S770 Health-Related Quality of Life With Ustekinumab vs Adalimumab for Induction and Maintenance Therapy in Biologic-Naïve Patients With Moderate-To-Severe Crohn’s Disease: IBDQ in the SEAVUE Study

Introduction: Crohn’s disease (CD) impacts physical and mental well-being, which can negatively affect health-related quality of life (HRQoL). The Inflammatory Bowel Disease Questionnaire (IBDQ), a disease-specific measure of HRQoL, was used to assess the effects of ustekinumab (UST) and adalimumab (ADA) on HRQoL in biologic-naïve patients with CD enrolled in the SEAVUE study. Methods: SEAVUE was a multicenter, randomized, blinded,...